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THE USE OF MICROCHIP CAPILLARY ELECTROPHORESIS/TANDEM 
MASS SPECTROMETRY FOR THE DETECTION AND QUANTIFICATION OF 
OPIOIDS 
 
BRIANNA DANIELLE SILVER 
ABSTRACT 
 Forensic toxicology is a critical field in which scientific techniques are employed 
in order to establish the presence or absence of pharmacological substances and/or their 
metabolites within an individual. The results of such analyses can have legal 
implications, and toxicology has a number of important applications, including post-
mortem investigations, workplace drug testing, therapeutic drug monitoring, and 
impaired driving studies.  
The focus of this specific body of work is on the use of toxicology in the detection 
and quantification of drugs of abuse –specifically opioids - in biological samples. In 
recent years, there has been a surge in opioid abuse and the need for forensic toxicology 
labs to process samples from such cases quickly and accurately continues to increase. As 
a result, it is imperative to research different techniques and technologies that can be 
applied in toxicology to improve efficiency of sample processing while still remaining 
sensitive and specific. 
 Many toxicology laboratories today use immunoassay techniques for screening, 
and utilize a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for 
quantification. While these methods are established and reliable, the need to analyze an 
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increasing number of samples in a more efficient time frame is essential, and with that, 
the need to develop and validate new analytical methods.  
 This study sought to validate the use of Microchip Capillary Electrophoresis-
Tandem Mass Spectrometry (CE-MS/MS) as a method for detecting and quantifying a 
panel of fourteen opioids. The experiments were run using a ZipChip (908 Devices, 
Boston, MA) as the separation scheme, which contains a small capillary where analytes 
are separated out by electrophoretic mobility - dictated largely by size and charge. These 
analytes were then ionized by electron spray ionization (ESI) at the end of the chip, and 
then detected, fragmented, and analyzed in a SCIEX 4500 Triple Quadrupole Mass 
Spectrometer (Framingham, MA). The analytical run time of the method evaluated was 
two and half minutes per sample. Calibration curves were run and the method was 
assessed for a number of validation parameters, including bias, precision, limit of 
detection, common analyte interferences, matrix interferences, and carryover, as 
recommended by the American Academy of Forensic Sciences Standards Board.  
 The fourteen drugs and metabolites looked at in this study were 6-
monoacetylmorphine, buprenorphine, codeine, dihydrocodeine, 2-ethylidene-1, 5-
dimethyl-3, 3-diphenylpyrrolidine (EDDP), fentanyl, heroin, methadone, morphine, 
naloxone, norfentanyl, oxycodone, oxymorphone, and tramadol. All standards were 
ordered from Cerilliant (Round Rock, TX), as well as deuterated internal standards used 
for quantification purposes. This study showed that as the method currently stands, it can 
reliably detect this panel of opioids at limits of detection between 1 and 15 ng/mL, with 
the exception of buprenorphine and morphine, for which the method appeared less 
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sensitive. While some applications desire higher sensitivity than this, this level of 
detection could be very useful as a screening technique that is quick and also far more 
specific than current immunoassay screening techniques, and provide the additional 
advantage of quantification for samples at slightly higher concentrations. Quality control 
samples at 100 ng/mL and 150 ng/mL generally showed consistent results and acceptable 
levels of bias and precision, indicating that the method can be used to reliably quantify 
this panel of opioids at those concentrations. In addition, interference signals detected 
during analysis of other common analytes often encountered with opioids were 
negligible, with the exception of heroin and norfentanyl. Analysis of ten lots of urine for 
blank matrix interferences also demonstrated low potential for interference, with the 
exception of heroin. Finally, there was no evidence of significant carryover between 
samples, or interference from the deuterated internal standards.  
While some potential instrumentation issues such as mass spectrometer 
calibration prompt further study, the method shows promise for future use as a high 
throughput analysis tool in forensic toxicology labs. CE-MS/MS has the added benefit of 
not only faster run times, but significantly less sample consumption per run, and 
additionally, less sample preparation. CE is a viable separation scheme for metabolites 
and forensic applications, and could make large impacts as an effective way to analyze 
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Drugs of Abuse & The Role of Forensic Toxicology 
 Forensic toxicology is defined as the analysis of biological samples for the 
presence of toxins, including drugs.1  The results from such analyses can then be used to 
provide information regarding the type and quantity of substances present within an 
individual, potentially for further legal applications concerning issues such as substance 
abuse, level of impairment, or cause of death.  
 In 2014, the Bureau of Justice Statistics reported that in the United States, public 
forensic laboratories processed over 566,000 samples - around 7% of which were 
classified as backlogged, and as many as 68% of labs had to outsource some services.2 
With such a high volume of samples annually, it is imperative to continue to further 
improve analytical methods and begin employing higher throughput techniques.  
 Although forensic toxicology can be used to identify both prescription drugs as 
well as over the counter compounds, this study focuses on its use for identifying drugs of 
abuse (DOAs) and/or their metabolites. A number of factors are indicative of a drug 
having potential for abuse, and they include (1) if there is evidence individuals are taking 
the drug outside of recommended parameters, or excessively enough to cause a hazard to 
their health and/or the safety of others, (2) there is significant distribution of the drug 
outside of legitimate vendors, and/or (3) it is a new drug specifically designed to mimic 
the effects of already existing drugs of abuse.3 The Controlled Substance Act (CSA) then 
schedules these drugs I-V based on their potential for abuse, with I being the highest.  
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DOAs span across different drug classes and cause different pharmacological 
effects, however, the method validation discussed here will focus on the detection of 
opioids, which fall under the class of depressants. In 2017, an estimated 70,237 people in 
the United States died from abusing drugs, and approximately 47,600 of those overdoses 
involved opioids.4  The opioid crisis is continuing to rise at an alarming rate, and with it, 
the need to analyze these samples quickly and effectively.  
History of Opioids  
Opioids are narcotics, and they can cause powerful analgesic effects, including 
feelings of euphoria, slowed breathing, drowsiness, dizziness, nausea and constipation.5 
Underneath the umbrella of opioids are both opiates - which can be natural such as 
morphine and codeine, or semi-synthetic, such as oxycodone and hydrocodone - as well 
as fully synthetic opioids, such as fentanyl. Natural and semi-synthetic opiates are 
derived from opium cultivated from the poppy plant, Papaver somniferum, while 
synthetic opioids are created chemically.5 Opioids as a whole traverse the entirety of the 
CSA schedule, with some such as heroin being designated as schedule 1, others such as 
fentanyl being schedule 2, and yet still others such as codeine in low concentrations 
(below 200 mg/mL), which is commonly found in cough medicines such as Robitussin, 
are schedule 5.3  
The use of opioids goes back thousands of years. Some of the earliest images 
depicted of the opium poppy date back to Sumerian times, and throughout history, this 
potent class of drugs has continued to play a role in determining the path of human 
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civilizations, from the 19th century opium wars, all the way up into the current opioid 
epidemic.6 
 Between 1999 and 2018, an estimated 450,000 people died from an opioid 
associated overdose, with both prescription and illicit opioids contributing to this 
number.7  The annual amount of deaths has trended upward over this time period, and 
presently, an estimated 128 people die per day of an opioid related overdose in the United 
States.7  
How exactly did this epidemic grow to become such a prominent problem? Looking 
back over the past 20-30 years, three general waves of increased opioid use can be 
observed, beginning with the rise in prevalence of prescription opioid use and abuse in 
the 1990s, and continuing through into the early 2000s.8 At peak prescription rates in 
2012, enough opioid prescriptions were dispensed in the United States that, if divided 
evenly across the population, could account for approximately 81 out of every 100 people 
having access to one9. In the most recent data for 2018, this number is down to 51 out of 
every 100 people – but this is still equal to over 168 million prescriptions nationwide.9  
This widespread availability is surmised to have played a catalytic role in the large 
spike of illicit opioid abuse that followed. On top of the staggering prescription statistics, 
factor in wave two - a steep rise in heroin abuse beginning in 201010 – followed by wave 
three – the growth of synthetic opioid abuse (particularly fentanyl) beginning in 201311 - 
and it’s clear why the country has such an extensive issue today.  
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Metabolism & Biological Mechanisms of Action of Opioids 
Opioid metabolism ultimately produces both active and inactive metabolites, which 
vary based on the drug used (Figure 1)12. The drugs themselves are generally lipophilic, 
which allows them to cross cell membranes easily. However, opioids also undergo 
substantial first pass metabolism in the liver to make them more hydrophilic and 
therefore easier to excrete.5 This generally occurs in two phases. Phase 1, involving the 
class of enzymes cytochrome P450 (CYP), modifies the drug in some way, often 
dealkylation or deamination. Phase 2 then conjugates the drug, most often to glucuronic 
acid, and following this glucoronidation, ultimately the drug is excreted.13 It is important 
to note that the CYP pathway is a common one for drug metabolism, and depending 
which specific CYP enzymes are required to metabolize a particular drug, interactions 























Because of the different CYP enzymes involved in modifying each specific drug, and 
the different genetic variants between individuals possible for each CYP enzyme, it can 
sometimes be difficult to predict exactly how quickly someone will metabolize a given 
opioid, and the severity and duration of the effects the substance may have on them.13 
This is important to remember for two reasons – one, it can sometimes have clinical 
applications and should be noted during therapeutic drug monitoring, as different patients 
who may react adversely to different specific opioids and need adjusted dosing. 
Secondly, in toxicology, since similar doses of drugs and metabolites can sometimes 
impair different individuals to varying degrees based on tolerance and metabolism, a 
wide range of concentrations can be present in samples. That is to say, while the general 
pathway of opioid metabolism is known, the rate at which drugs are metabolized and 
excreted may vary, and this should be noted when interpreting forensic toxicology 
results.  
Our understanding of the precise neurobiological mechanisms by which opioids cause 
their effects continues to evolve over time. It is generally agreed upon that the analgesia 
they induce is driven by opioids’ ability to mimic the activity of endogenous peptides 
such as beta-endorphin, enkephalins and dynorphins and their interactions with the mu, 
kappa, and delta receptors in the brain.14 When either endogenous peptides or opioid 
agonists bind to these receptors, both ion channel modulation - and consequently cellular 
pathways - are altered. These G-protein coupled receptors show distinct but sometimes 
overlapping gene expression patterns in both the central and peripheral nervous systems, 
and each has varying affinities for specific opioids, as well as different contributions to 
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their overall effect.15 The most thoroughly characterized receptor to date is the Mu opioid 
receptor (MOR), and its agonists (such as morphine, codeine, and tramadol) cause 
generalized central nervous system depression, and alleviate pain.5 Additionally, 
activated MORs are proposed to cause hyperpolarization of interneurons, thereby 
reducing Gamma-aminobutyric Acid (GABA)-mediated synaptic input into dopamine-
containing cells, which in turn increases the activity of downstream dopamine pathways. 
This results in feelings of reward and euphoria when using the drug, and is thought to 
contribute to its addictive properties.16 
 While MORs are proposed to be the main driver behind opioids’ analgesic affects, 
conversely agonists for kappa opioid receptors (KORs) can actually cause dysphoria and 
stress by decreasing dopaminergic neuronal activity, particularly in the nucleus 
accumbens.17  Meanwhile, agonists for delta opioid receptors (DORs) are known to 
reduce anxiety, and can act in a few different ways, such as modulating calcium ion 
channels, and coupling with MORs to create MOR/DOR heterodimers.18  
Unsurprisingly, continued use of opioids alters the body’s natural balance of these 
receptors and their downstream cellular pathways, and addiction and tolerance can 
develop. Opioids are highly addictive, and after just a few weeks of repeated abuse, users 
can experience intense physical withdrawal symptoms within eight hours of cessation. 
This is because the same dopaminergic pathways that become hyper-activated when 
taking the drug become downregulated without it. Dopamine firing drops below even 
normal levels when the drug is taken away, with dopamine neurons decreasing in size, 
and dopamine receptors becoming more sensitive to antagonists.19 This causes addicts to 
	
7 
seek out and consume more of the substance in order to function at just a baseline 
normality.20  
Over this same time period, tolerance keeps building, and an individual will take 
more and more of the drug in order to feel its effects. It’s important to note that on a 
molecular level, tolerance is proposed to develop at different rates for different receptors, 
and even amongst different locations in the body within a single type of receptor.20 This 
makes continued abuse particularly risky – consider that a user may develop tolerance to 
the pain-relieving effects at a far faster rate than for instance respiratory depression, and 
this can lead to overdose and death.20  Molecular mechanisms driving tolerance are 
thought to include MOR/DOR heterodimers, with co-expression of DOR and MOR in the 
dorsal root ganglion correlating with an increased ability to build tolerance. Conversely, 
the use of antagonists specifically for DORs diminished this effect.21  
There is evidence that chronic abuse of opioids even leads to epigenetic changes 
within the brain of an individual, doubtlessly influencing consequent behavioral changes. 
Recent research has shown higher levels of acetylation of histone H3 can be observed 
throughout the mesolimbic dopamine system in chronic users, thereby unwinding 
chromatin and permitting access to higher levels of transcription, though more research 
has to be done on specific genes upregulated and their role in addiction and behavior.22 
Going hand in hand with this finding, methylation of histone H3 seems to be 
downregulated in chronic opioid users, once again allowing for an increase in 
transcription of normally suppressed genes, such as FosB in the nucleus accumbens – a 
transcription factor known to play a role in promoting drug addiction.23 These changes 
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are just the beginning of our understanding on how opioid abuse can affect the brain, and 
at least a portion of these changes likely continue long after cessation of use. It is unclear 
at this time if some of these gene expression changes are heritable through generations.  
Taken together, the massive biological impact opioid abuse can have only reiterates 
the importance of being able to quickly and accurately detect these drugs and their 
metabolites in toxicological samples. Toxicology can be employed not only as a method 
for identifying opioid users and addicts, but continued drug monitoring is essential in 
helping individuals on the road to recovery. There is no doubt that opioid abuse wreaks 
mental and financial havoc on this country, but continued research into improving 
toxicological methods can hopefully play a role in helping to ease this burden.  
Capillary Electrophoresis Versus Currently Utilized Separation Methods 
 Currently, the most common toxicological technique for detecting and quantifying 
opioids in biological samples generally involves either gas or liquid chromatography as 
the separation scheme, and mass spectrometry for detection. While these methods are 
reliable, there are a number of advantages to pursuing capillary electrophoresis (CE) as a 
potential separation method. First, CE methods can be much faster than those for 
chromatography, allowing for higher throughput analysis of samples. Second, less sample 
preparation is necessary for CE based separation, and less sample can be consumed in 
each analysis.  
 While the goal of both methods is to separate drugs and metabolites within a 
sample so that they can be distinguished from one another and identified, there are some 
fundamental differences between the two methods. In chromatography, compounds are 
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separated based on their differential affinities for the stationary phase within the column 
which they are passing through, and the mobile phase, effectively causing metabolites to 
travel through the column at different rates dependent on their polarity and size. CE on 
the other hand is an electrokinetic technique in which analytes move through a capillary 
with an applied voltage and are separated by their electrophoretic mobility, which is 
dependent on the structure, size, and charge of the molecule.24  
ZipChip Technology 
 The ZipChip is a microfluidic chip which separates analytes by capillary 
electrophoresis, before expelling them via electron spray ionization into the mass 
spectrometer for detection.25, 26 As seen in the schematic below (Figure 2), the chip 
contains four wells, each of which serves a specific purpose. Background Electrolyte 
(BGE) consisting of 2% formic acid in a solution of 1:1 water and methanol, fills the 
capillary channel, and is placed into both wells 2 and 4, while the sample is loaded into 
well 3. To inject the sample, pressure is applied by a micropump to wells 2 and 3, and a 
desired volume between 1-10 nL can be injected and travel to the injection cross.25, 27, 28 
At this point, a differential voltage is applied to wells 2 and 4, thereby generating an 
electrical field gradient which will separate out the metabolites by electrophoresis as they 
travel through the capillary.25, 29 Cations travel towards the ESI corner of the chip at 
different rates based on charge and molecular structure, anions migrate towards the BGE 
well 2, and neutral molecules are pushed towards the waste well, or well 1, because of 
residual electroosmotic flow. This in part is why limited sample prep is required for this 
particular method – the sample is effectively desalted and cleaned, and unwanted 
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negative and neutral ions are eliminated during this step. For analysis, samples need only 
be diluted in metabolite diluent containing methanol and ammonium acetate, which 
provides the leading ion for the electrophoresis, and narrows the resulting bands for 
improved temporal resolution. This, along with the capillary being much shorter than 
traditional columns in LC methods, helps to limit diffuse or dissociated peaks, and create 
sharper bands on the resulting electropherogram. Additionally, as molecular structure 
affects the way in which metabolites are separated with CE, theoretically, structural 





Figure 2: ZipChip Schematic. Left: External view of the ZipChip. Right: Internal 
schematic of the ZipChip. Figure by 908 Devices Inc. (Boston, MA)25. 
Once metabolites have travelled through the capillary and reach the ESI tip, a 
steady stream of charged droplets are emitted. These charged spheres become smaller and 
Well 1 




smaller as the solvent evaporates, causing a higher overall charge density. Because of 
coulombic repulsion, this causes an increase in surface tension until eventually the 
droplet reaches the Rayleigh limit.30 Droplets at this limit undergo a “coulombic 
explosion”, and break down into nanodroplets. From these nanodroplets, analyte ions are 
liberated, which enter the mass spectrometer where they are ultimately detected.31 
Triple Quadrupole Mass Spectrometry 
A mass spectrometer contains an inlet or ionization source, a mass analyzer, and a 
detector, and it can be used to provide both qualitative and quantitative data for any given 
sample. In this case, the ionization source is the ESI described above, the mass analyzer 
is a triple quadrupole, and the detector records the mass to charge ratio of the resulting 
ions, thereby aiding in identification of drugs within the sample.  
As implied by the name, a triple quadrupole mass spectrometer like the one used here 
contains three quadrupoles. The first and third (Q1 and Q3, respectively) act as mass 
filters, and each is essentially made up of two pairs of metal rods – one which modulates 
the direct current (DC) and one which regulates the radio frequency (RF). Together, by 
changing the parameters of the DC and RF potentials, specific ions can be selectively 
released from the quadrupole based on their mass to charge ratio (m/z), while others are 
not. The second quadrupole, or the collision cell, q, is only controlled by RF potential.32  
The first quadrupole, Q1, scans for the precursor ion’s m/z, as the molecule is intact 
at this point. These select precursor ions are then filtered into the second quadrupole, q, 
which contains an inert gas that breaks the molecule in predictable ways based on the 
differing strength of chemical bonds. In this way, molecules with similar precursor ion 
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masses can be distinguished from one another, as the m/z of unique select product ions 
resulting from a particular analyte of interest’s molecular structure can be selected for in 
Q3. The detector then records the intensity of the signal, thereby aiding in the 
quantification of the analyte of interest.  
 Research Objectives 
 The goal of this research project was to develop and validate a method for the use 
of microchip capillary electrophoresis/tandem mass spectrometry (CE-MS/MS) for the 
reliable detection and quantification of opioids. This was done using a ZipChip (908 
Devices Inc., Boston, MA), which is a microfluidic device which separates analytes via 
Capillary Electrophoresis, and then ionizes them using Electron Spray Ionization (ESI). 
The analytes were then detected by a SCIEX 4500 Triple Quadrupole Mass Spectrometer 
(Framingham, MA).  
 For the development of this method, a panel of 14 analytes were tested: 6-
monoacetylmorphine (6-MAM), buprenorphine, codeine, dihydrocodeine, 2-ethylidene-1, 
5-dimethyl-3, 3-diphenylpyrrolidine (EDDP), fentanyl, heroin, methadone, morphine, 
naloxone, norfentanyl, oxycodone, oxymorphone, and tramadol. All standards were 
ordered from Cerilliant (Round Rock, TX), and diluted in metabolite diluent (908 
Devices Inc.) consisting of methanol and ammonium acetate for analysis. Corresponding 
deuterated internal standards (Cerilliant) were utilized for quantification of each analyte, 
with the exception of naloxone, which was compared to the deuterated internal standard 
for fentanyl, due to its having a similar migration time. Blank lots of urine were also run 
to assess matrix interference, as well as mixtures of other commonly found drugs to 
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assess common analyte interferences. Dilution was the only sample preparation used for 
all of these analyses. The American Academy for Forensic Sciences Standards Board 
(ASB) validation guidelines outlined in “Standard Practices for Method Validation in 
Forensic Toxicology”33 were used to develop a calibration model and measure bias, 
precision, carryover, limit of detection, and interferences.	
 MATERIALS AND METHODS 
 CE –MS/MS Software Platforms 
The ZipChip platform was used as the separation scheme for this method, and the 
ZipChip Software by 908 Devices Inc. (Boston, MA) was used for setting up and running 
the autosampler and ZipChip unit parameters. The software used to collect data produced 
by the SCIEX 4500 Triple Quadrupole mass spectrometer was Analyst from SCIEX 
(Framingham, MA), and further analysis and quantification was done using Skyline 
(University of Washington, Seattle, Washington).  
Drug Standards and Reagents 
All drug standards as well as deuterated internal standards used in this method were 
purchased from Cerilliant (Round Rock, Texas). The 14 drug standards used were  6-
MAM, buprenorphine, codeine, dihydrocodeine, EDDP, fentanyl, heroin, methadone, 
morphine, naloxone, norfentanyl, oxycodone, oxymorphone, and tramadol. The 
deuterated internal standards used were 6-MAM-D6, buprenorphine-D4, codeine-D6, 
dihydrocodeine-D6, EDDP-D3, fentanyl-D5, heroin-D9, methadone-D9, morphine-D6, 
norfentanyl-D5, oxycodone-D6, oxymorphone-D3, and tramadol-13C-D3. With the 
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exception of buprenorphine, all drug standards were purchased at a starting concentration 
of 1 mg/mL. Buprenorphine, and all deuterated internal standards, were purchased at a 
concentration of 100 µg/mL. All standards came prepared in methanol, with the 
exception of heroin and 6-MAM, which were in acetonitrile. 
For analysis, all standards were diluted in ZipChip metabolite diluent, consisting of 
methanol and ammonium acetate. The ZipChip itself as well as the autosampler were 
always primed with ZipChip metabolite BGE, made up of 2% formic acid in a solution of 
equal parts methanol and water.  
Urine for the blank matrix interference study came from donated samples collected 
following Institution Review Board (IRB) guidelines at the Boston University School of 
Medicine (Boston, MA).  
Compound Optimization and Building the Multiple Reaction Monitoring (MRM) 
Method 
Precursor and product ions were first researched using a technote from Sciex.34 From 
there, manual infusions were run for each of the individual compounds to be analyzed. 
Each compound was diluted to a concentration of 10 ng/mL in BGE, and optimization 
was run in groups of 2-3 target compounds at a time, with each group containing 
compounds of significantly different molecular weights from one another (at least 25 
amu). This was to avoid misidentification of isobaric compounds, and allow parameters 
to be optimized for each specific compound individually. These manual infusions 
allowed the ZipChip to continue running, ionizing the product and inputting it into the 
mass spectrometer for an unlimited amount of time. Meanwhile, precursor and product 
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ions were input into the SCIEX Analyst software, as well as a range of collision energies 
from 5 to 55 with a step size of 10. As the manual infusion continued on, a scan for the 
precursor Q1 ion was performed, and then a mass spectra of the product Q3 ions was 
generated. Product ions were chosen based on the SCIEX technote and the intensity of 
the signal for the fragment. Analyst software then generated a report containing the 
optimal declustering potentials, the collision energy, and the collision exit cell potential 
for the product ions, and these parameters were incorporated into the multiple reaction 
monitoring (MRM) method.  
Once all the MRM settings were optimized, migration times were determined for the 
compounds and deuterated internal standards. This was done by combining all 
compounds together in one mixture, with each compound at a concentration of 100 
ng/mL. This mixture was then run for a total of 3 minutes, and the mass spectrometer 
settings included a precursor ion scan range of 150-500 m/z, positive polarity, sheath 
pressure of 2-3 psi, and Q1 resolution of 0.7. Five separate mixtures were run and the 
average migration times for each compound used as the baseline for the method.  
The tables below show both the ZipChip inputted software parameters, as well as the 
developed MRM method parameters, which were inputted into the SCIEX Analyst 
software for future runs. It is important to note that injection volume, in Table 1, is 
distinct from sample volume, found in Table 2. Sample volume is the amount of sample 
transferred from the autosampler to the sample well on the chip, but the injection volume 















10 nL 1000 
V/cm 
HS Metabolites 30 
seconds 
 













































6-MAM 328.1 165 11 59 6 1.54 
6-MAM-D6 334 165 41 59 6 1.54 
Buprenorphine 468.3 414.2 131 43 14 1.97 
Buprenorphine-
D4 
472.3 400.2 191 55 10 1.97 
Codeine 300.1 165 41 37 8 1.43 
Codeine-D6 306.2 218.1 51 37 10 1.43 
Dihydrocodeine 302.1 199.1 46 49 8 1.45 
Dihydrocodeine-
D6 
308.2 171.2 16 29 12 1.44 
EDDP 278.1 186 26 45 12 1.30 
EDDP-D3 281.3 234.2 191 41 10 1.29 
Fentanyl  337.1 105.1 41 53 10 1.63 
Fentanyl-D5 342.3 105.1 31 61 10 1.62 
Heroin 370 165 46 65 6 1.54 
Heroin-D9 379.2 61.2 146 57 4 1.54 
Methadone 310.1 265 46 21 10 1.45 
Methadone-D9 319 268 41 25 10 1.45 
Morphine 286 165 46 81 20 1.49 
Morphine-D6 292.1 152 71 85 14 1.49 
Naloxone 328.1 253.1 11 15 10 1.75 
Norfentanyl 233.1 84.1 26 39 6 1.32 
Norfentanyl-D5 238.2 84.1 136 39 8 1.32 
Oxycodone 316.1 241.1 41 47 14 1.48 
Oxycodone-D6 322.1 247.1 216 39 10 1.47 
Oxymorphone 302 227.1 21 47 20 1.53 
Oxymorphone-
D3 
305.1 230.1 91 39 12 1.52 
Tramadol 264.1 58.1 111 51 6 1.44 
Tramadol-13C-
D3 





Quantification of Analytes 
	 All results from the calibration curve, carryover, and quality control studies were 
quantified using Skyline (University of Washington). The ratio of the peak area from the 
analyte of interest was compared to that of the corresponding internal standard, as within 
each sample, deuterated internal standards were consistently included at a concentration 
of 100 ng/mL, while the concentration of the target analyte was at the specified 
concentration for that particular sample. This helps to ensure that even if signal intensity 
varies slightly between samples, quantities can still be accurately determined, as quantity 
is calculated based on the ratio of the peak areas, and not their absolute areas. Figure 3 
shows the results for methadone in the initial proof of concept calibration curve run to 




Figure 3: Results from a Calibration Curve for Methadone. This figure demonstrates the 
analysis performed in Skyline (University of Washington) in order to quantify analytes. 
In each graph, the red peak represents the analyte of interest, while the purple peak 











Calibration Curve & Carryover 
Once the MRM method settings had been established, calibration curves were run 
using the developed method. The concentrations analyzed for the calibration curves were 
0.5, 5, 15, 50, 75, 100, 150 and 200 ng/mL. Results were quantified as described above 
and curves were then accepted if, when using at least six of the eight calibrator points and 
linear 1/x weighting, an R^2 value was achieved of .95 or higher.  
 Samples were prepared by first making a stock solution with all the drug standards at 
a concentration of 10,000 ng/mL, which was then serially diluted to further stocks of both 
1,000 ng/mL and 100 ng/mL, all in metabolite diluent. A separate solution with all of the 
internal deuterated standards was also made at a concentration of 10,000 ng/mL, also in 
metabolite diluent. Using these stock solutions, 500 µL samples for each of the 
calibrating concentrations were then made, using the proper dilutions, once again in 
metabolite diluent. In each sample, 5 µL of the deuterated internal standard stock were 
included, for an internal standard concentration of 100 ng/mL in every sample.  
Samples were then run from low to high concentration using the MRM method. 
Following the highest calibrator, a double blank sample (metabolite diluent alone) was 
run to assess carryover. Finally, a blank sample of just deuterated internal standards alone 
was run, again to look for any potential interfering signals from the deuterated standards 
themselves. After an initial calibration curve run as a proof of concept, five separate 




 Quality Control Samples for Bias & Precision Analysis 
Bias and precision were analyzed at low, medium, and high concentrations, which in 
this case were designated as being 5 ng/mL, 100 ng/mL, and 150 ng/mL. This was done 
by running samples in triplicate at each of these concentrations, for five separate runs. 
Bias was calculated as: 
 Bias = ((grand mean – nominal concentration)/nominal concentration)*100 
Grand mean is the average value from all replicates over all runs, and the nominal 
concentration is either the low, medium, or high concentration value. This was done for 
each of the concentrations.  
The %CV, or percent of coefficient of variation, was calculated to obtain both within 
run and between run precision values. %CV for within run precision was calculated as: 
 Within run %CV = (standard deviation of a single run/mean value of a single 
run)*100 
And between run %CV was calculated as: 
 Between run %CV = (standard deviation of all runs/grand mean)*100 
These calculations were once again done for each of the three designated quality 
control concentrations. The goal of this validation was to obtain values for each within 
+/- 25%.  
Limit of Detection & Limit of Quantification 
It was the intention of this study have the lowest non-zero calibrator, .5 ng/mL, be 
analyzed as the LOD and LOQ by running samples in triplicate at this value over three 
separate runs, and assessing the bias and precision results. However, it became clear that 
	
22 
with the current tuning of the mass spectrometer and/or the state of the method, this value 
was not feasible as the signal it produced was not high enough over noise to be 
consistently detected. Therefore, a different approach was used to calculate LOD with the 
given results of this particular validation. In alignment with ASB validation guidelines, 
the following equation was used: 
LOD=(3.3*standard deviation of the y intercept of the calibration curves)/average 
slope of calibration curves 
This was done using the averaged values obtained from the linear equations of the 
five calibration curve runs, and serves as the current LOD given the settings during this 
particular validation study.  
Blank Matrix and Common Analyte Interferences 
Ten lots of blank urine were analyzed to look at potential blank matrix interferences 
that could be observed as the method moves towards analyzing actual biological samples. 
This was done by analyzing ten different urine samples, and recording the highest signal 
observed over the course of the run of each sample for each of the fourteen drugs. 
In addition, three different mixes of analytes commonly encountered in samples 
found to have opioids were also analyzed for signal interferences. Often times, other 
drugs and analytes can be found in samples in combination with opioids, and it is 
important they do not alter the signal of the developed method. The mixes were as 
follows:  




Mix 2- benzoylecogonine, cocaine, lidocaine, norcocaine 
Mix 3 - amphetamine, methamphetamine, MDA, MDEA, ethylone, alpha-PVP, 25I-
NBOMe, amitriptyline, citalopram, fluoxetine, trazadone, PCP, LSD 
Each of these samples was diluted in metabolite diluent to a concentration of 200 
ng/mL, and once again the highest signal given over the course of the run for each of the 
fourteen target drugs were recorded, and compared to average signal values for low 
concentrations of the target analytes to assess for potential interferences.  
 RESULTS 
Analyte Detection & Migration Time  
All fourteen analytes were detected using the MRM method. While the method ran 
for a total of two and a half minutes to ensure all compounds had eluted, all analytes were 
detected between approximately time markers 1 minute 15 seconds, and 2 minutes and 10 
seconds. Although many of the similarly structured analytes eluted at similar time points 
during this window, they were able to be distinguished from another by the triple 











Figure 4: Migration times of the Fourteen Target Analytes. Seen as depicted in Skyline. 
Calibration Curves 
Table 4 shows the R^2 values for the five calibration curves, with 1/x weighting. For 
each curve, a minimum of six of the eight calibrators were used for the calculation. All 






Table 4: R^2 For The Five Calibration Curves 
Bias and Precision   
Bias was calculated in order to assess how close to the anticipated value the results 
for each analyte over each run were, while precision indicates how reproducible those 
results are, both within a single run and over multiple runs. These calculations were done 
on each of the three quality control concentrations, 5, 100, and 150 ng/mL, and the results 
can be seen below in tables 5-9. The goal for both percent bias and precision was to be 
with +/- 25% for each compound at each concentration.  
Nearly all compounds demonstrated acceptable bias for the 100 and 150 ng/mL 
concentrations, with the exception of naloxone at 150 ng/mL. However, the 5 ng/mL 
concentration results were less consistent, and demonstrated much higher bias. 
Specifically, heroin, methadone, morphine, naloxone, oxyocodone and oxymorphone 
Compound Run 1 Run 2 Run 3 Run 4 Run 5 
6-MAM 0.9967 0.9625 0.9892 0.9796 0.9968 
Buprenorphine 0.9944 0.9968 0.9842 0.9915 0.969 
Codeine 0.9584 0.9962 0.9967 0.9929 0.9772 
Dihydrocodeine 0.9852 0.9763 0.9905 0.9584 0.964 
EDDP 0.9918 0.9949 0.9831 0.9612 0.9968 
Fentanyl 0.9997 0.9982 0.996 0.9973 0.995 
Heroin 0.9854 0.9899 0.9569 0.997 0.9809 
Methadone 0.9611 0.9507 0.9927 0.9967 0.9522 
Morphine 0.9546 0.8852 0.9926 0.9747 0.9872 
Naloxone 0.9756 0.9857 0.9905 0.9602 0.9895 
Norfentanyl 0.9709 0.9529 0.9942 0.9965 0.9901 
Oxycodone 0.9745 0.9818 0.9945 0.953 0.9875 
Oxymorphone 0.9853 0.9945 0.9744 0.9839 0.9743 
Tramadol 0.9873 0.9877 0.9795 0.9962 0.9971 
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failed to meet the intended goal of a bias within +/- 25%. This suggests that the 
quantification accuracy at 5 ng/mL could be improved. 
The between run precision results followed a similar trend, with nearly all compounds 
demonstrating acceptable precision at the 100 and 150 ng/mL concentrations, with the 
exception of heroin and naloxone at the 150 ng/mL concentration, and dihydrocodeine, 
naloxone, and oxycodone at the 100 ng/mL concentration. However, only three drugs 
demonstrated acceptable precision at the 5 ng/mL concentration – EDDP, fentanyl, and 
norfentanyl.  
Finally, the within run precision results solidify the method’s ability to overall 
reliably quantify the target analytes at 100 and 150 ng/mL, but not at 5 ng/mL. At 150 
ng/mL, all compounds demonstrated acceptable precision across all runs with the 
exception of  6-MAM, buprenorphine, morphine, and oxycodone, which demonstrated 
acceptable bias across four of the five runs, and naloxone, which only showed acceptable 
bias in two of the five runs. At 100 ng/mL, codeine, EDDP, fentanyl, heroin, and 
tramadol demonstrated acceptable precision in all five runs, while 6-MAM, 
buprenorphine, methadone, morphine, and oxycodone achieved the same in four out of 
five runs, and finally, dihydocodeine, naloxone, norfentanyl, and oxymorphone met this 
minimum in three of the five runs.  
At 5ng/mL, results varied wildly, and the %CV values on the whole tended to be 
much higher than at the other concentrations. 6-MAM, buprenorphine, EDDP, and 
fentanyl showed acceptable precision in four out of five runs; oxymorphone and tramadol 
in three out of five runs; methadone, morphine, and norfentanyl, in two out of five runs; 
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and codeine, dihydrocodeine, heroin, and naloxone, in one out of five runs. Oxycodone 
did not show acceptable precision at 5 ng/mL for any run.   
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7.42 108.26 186.79 48.3 8.26 24.5 
Tramadol 
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Buprenorphine 
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Dihydrocodeine 









































































































4.74 10.56 38.39 64.67 9.57 21.67 
Tramadol 
1.3 8.89 21.23 28.42 9.07 13.98 
	
29 
Table 7: Within run precision results for 5 ng/mL 






































































































































16.46 14.71 23.24 267.4 30.9 
Tramadol 









Table 8: Within run precision results for 100 ng/mL 






































































































































2.83 20.46 29.53 15.45 38.35 
Tramadol 









Table 9: Within run precision results for 150 ng/mL 






































































































































13.99 16.16 8.33 17.84 7.56 
Tramadol 








 Limit of Detection  
Based on the lack of bias and precision evident in the results for the 5 ng/mL 
concentration, it became clear that the limit of detection seemed to be higher than 
previously thought based on the initial test run in November, which was assumed to be 
the lowest calibrator used at the time, 0.5 ng/mL. Therefore, a new approach was used to 
calculate the limit of detection for the results present from these five runs. Using the 
equation (3.3*std deviation of the y intercept)/average slope, and the data from the 
calibration curves, the calculated LODs are shown in table 10.  
Table 10: Calculated LOD for the Calibration Curves  
















These results quite clearly help show why the quality control samples did not 
demonstrate the desired bias and precision in the lowest quality control concentration 
pool of 5 ng/mL. Given the current settings of the method, and how the mass 
spectrometer was calibrated at the time, only six of the compounds had limits of detection 
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below 5 ng/mL. These results indicate that the low concentration samples (though not the 
medium and high concentrations) were doubtlessly impacted by noise, as the overall 
signal was not as high as anticipated, yielding erratic results for the lowest quality control 
samples.  
Comparison of Signal Between Test Run, and Calibration Curves/Quality Control 
Runs 
After suspecting differences in calibration following the initial proof of concept 
run and the five runs used for the final analysis, maximum peak signal heights were 
compared between the results for the three 5 ng/mL samples run during the initial run, 
and the overall average 5 ng/mL signal for the five calibration curve runs. The signal for 
the original test run was found to be much higher across the board – in the most extreme 
example, the signal intensity was 47.9 times higher for the 5 ng/mL samples of 
methadone in the original run than the average of the five calibration curve runs. The 
smallest difference was seen in heroin, where the signal in the original run was only 
about 2.9 times higher. These discrepancies in signal intensity could help explain why 
during the calibration curve runs, the 5 ng/mL concentration pool experienced so much 
variation – the signals were extremely low, and for nearly all analytes maximum signal 

















5 ng/mL in 
Calibration 
Runs 
6-MAM 3232 432.5 
Buprenorphine 4156 988.9 
Codeine 2171 258.7 
Dihydrocodeine 26353 714.1 
EDDP 23023 800.7 
Fentanyl 8714 3071.9 
Heroin 4184 345 
Methadone 37409 781.4 
Morphine 2854 321.9 
Naloxone 1263 266.9 
Norfentanyl 6147 1763.9 
Oxycodone 6473 205.2 
Oxymorphone 6919 269.7 
Tramadol 83678 3804.9 
Blank Matrix Interference 
Ten separate lots of blank urine provided through IRB donations at the Boston 
University School of Medicine were analyzed, and their signal was compared to the 
signals generated by the analytes in the five calibration runs, as these were run around the 
same time, and those results would likely be closest in spectrometer calibration settings 
for a fair comparison. In the table below, the maximum signal intensity for each of the ten 
lots is recorded, as well as averages for the 5 and 15 ng/mL concentrations of each drug 














Overall, urine appears not to cause an interfering signal, particularly when compared 
to the 15 ng/mL samples (see last column, Table 13), which is a concentration above the 
LOD for all compounds other than buprenorphine and morphine. The only compounds 
which show potential interferences from the blank matrix at that concentration are heroin 
in six of the lots, morphine in one lot, and tramadol in one lot. Interestingly, lot #10 
seems to have a genuine and very high signal for tramadol, indicating perhaps a real 
presence of the drug in this sample. Given the anonymous nature of the donations, this 
could be the case, but it isn’t possible to know for sure without further testing using a 






















187 345 0 443 187 395 367 233 159 314 
Buprenorphine 465 1000 381 592 0 527 930 541 418 987 
Codeine 200 206 128 59 52 0 117 107 115 227 
Dihydrocodeine 0 267 280 138 161 248 128 130 188 63 
EDDP 33 65 100 132 100 138 34 349 0 341 
Fentanyl 713 1244 1995 659 407 1353 547 2956 965 1918 
Heroin 453 496 410 513 289 554 547 540 506 176 
Methadone 426 351 700 113 756 484 366 435 228 331 
Morphine 189 0 66 779 144 135 102 273 217 260 
Naloxone 25 37 44 65 73 12 5 113 81 144 
Norfentanyl 210 295 142 47 292 248 33 323 169 396 
Oxycodone 62 0 158 0 69 53 0 60 107 107 
Oxymorphone 0 50 80 101 0 20 115 0 55 14 
Tramadol 1816 2529 3108 1320 4358 3069 1681 1405 1724 29642 
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Common Analyte, Blank and Double Blank Interferences 
For common analyte interferences, three different mixtures of drugs commonly 
encountered in forensic samples which also contain opioids were analyzed. Mix 1 
included alpha-hydroxyalprazolam, clonazepam, 7-aminoclonazepam, diazepam, and 
etizolam; mix 2 included benzoylecogonine, cocaine, lidocaine, and norcocaine; and mix 
3 included amphetamine, methamphetamine, MDA, MDEA, ethylone, alpha-PVP, 25I-
NBOMe, amitriptyline, citalopram, fluoxetine, trazadone, PCP, and LSD. All drugs were 
run at a concentration of 200 ng/mL.  
The highest signal recorded across the entire two and half minute method was 
recorded, and compared to the average 5 and 15 ng/mL signals for each analyte. 
Additionally, the average signal from five different double blanks, which contained 
metabolite diluent alone, were also assessed. These double blanks were run immediately 
after the highest calibrator in order to see if any carryover was observed. Finally, the 
highest signals given from five blank samples which included only the deuterated internal 
standards, and not the drug standards, were also averaged for the highest signal they 
yielded using the method, in order to insure they were not artificially inflating any 
quantitation. Table 13 shows these results.  
Overall, the commonly encountered drugs did not cause a concerning level interfering 
signal when compared to the 15 ng/mL samples for the target analytes, other than heroin, 
where all three mixes generated higher signal, and norfentanyl, where mix 3 generated a 
higher signal. None of the double blanks generated signals higher than the 5 or 15 ng/mL 
target analyte signals, demonstrating that metabolite diluent does not interfere with 
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analysis. Additionally, none of the blank samples, or samples with contained internal 
standards alone, generated a signal higher than either the 5 or 15 ng/mL samples either, 
indicating the internal standards do not interfere with proper detection of the target 
analytes.  
Table 13: Common Analyte Interferences & Carryover Assessment Signal 
Compound Mix #1  
(200 
ng/mL) 




















6-MAM 519 413 346 221.2 187 432.5 1174.2 
Buprenorphine 1284 247 838 316.8 377.6 988.9 2150.4 
Codeine 113 208 103 135.2 44.2 258.7 475 
Dihydrocodeine 137 202 425 133.6 179.8 714.1 1436.2 
EDDP 99 69 35 61.4 58 800.7 1220.2 
Fentanyl 667 426 375 648.4 445 3071.9 13134.2 
Heroin 793 595 1041 238 164.4 345 484.4 
Methadone 616 501 719 393.6 260.6 781.4 2572.6 
Morphine 325 187 216 263.4 172.6 321.9 643.8 
Naloxone 12 25 72 25.8 54.2 266.9 770.6 
Norfentanyl 964 1021 4435 528.2 539.8 1763.9 4094.2 
Oxycodone 138 100 0 53 32 205.2 191.8 
Oxymorphone 65 180 50 52.4 131.6 269.7 768.6 





This development and validation serves as a starting point for continued improvement 
of the method created here, which demonstrates that while all drugs in the method were 
able to be reliably detected, consistent quantification at lower concentrations can be 
improved upon. 	
Overall, results for the detection and the limits of detection for the fourteen analytes 
discussed here were very promising for concentrations generally above 5 ng/mL, 
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although less reliably so for concentrations below this threshold. Regardless, for many of 
the analytes in this method, the current limits of detection may be good enough to 
identify common concentrations found in those who consume the drug. Additionally, this 
perceived lack of sensitivity seems likely at least in part due to a miscalibration of the 
mass spectrometer during the time of these runs, as the original test run yielded far higher 
signals for equal concentrations of the analytes assessed. With recalibration, and some 
further tuning of the method, the lower concentration samples can be more easily 
distinguished from noise, the limits of detection can be lowered further, and firm limits of 
quantification can be established.  
In its present state, the method is reliable for quantification of concentrations low 
enough for most purposes. For instance, one study found that for fentanyl, one of the 
most potent of the drugs analyzed here - and thereby likely to be found in lower 
concentrations - had biological levels in post-mortem samples that averaged around 11 
ng/mL in femoral blood, and 97 ng/mL in urine.35 The LOD for fentanyl for this method 
is 4.03 ng/mL, well within the range of being able to detect such samples. While non-
lethal doses would arguably be found in considerably lower quantities, this points to the 
fact that, depending on the context, further increased sensitivity may not be necessary.  
For instance, workplace drug testing often screens for morphine in urine at 
concentrations of 2,000 ng/mL.12 This is partially because generally, the target 
demographic of workplace drug testing is not particularly likely to abuse drugs, and also 
to eliminate any chance of false positives from substances such as poppyseeds. In clinical 
settings, a commonplace cutoff screening threshold for many immunoassay screening 
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tests for opioids is 300 ng/mL of morphine.12 The CE/MS-MS method described here is 
more than sensitive enough to be used in such contexts, and as a potential screening 
method it has the benefit of being both fast, but still far more specific and informative 
than general immunoassay techniques. While most immunoassay screening methods only 
test for morphine, a common metabolite of most opiates, the CE-MS/MS method can 
differentiate between the fourteen drugs in this panel, and likely others as well. 
Additionally, it can reliably detect and quantitate at levels much lower than the thresholds 
required for the applications described above. However, it can still be improved upon for 
the very lowest concentrations, which may be necessary in situations such as therapeutic 
drug monitoring, or to detect synthetic opioids such as fentanyl and buprenorphine in 
contexts of lower consumption.  
Calibration Curves 
The calibration curves using a 1/x linear weighting and at least six of the eight 
calibrator points all had R^2 values of greater than .95, with the exception of one run for 
morphine. In fact however, these R^2 values are probably lower than they could be, given 
that with the current instrument settings and calibrations, the limit of detection was 
realized after to be higher than one or two of the lower calibrator points (.5 and 5 ng/mL) 
for some of the compounds. In the future, rerunning either the same calibration curves 
with a recalibrated and tuned mass spectrometer, or running calibration curves starting at 
a higher concentration, would certainly help to improve the R^2 values and make the 
curves more consistent, and as a result, the reliability of the quantitation model.  
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Bias & Precision  
Bias and precision clearly lacked in the 5 ng/mL quality control samples, but this 
makes sense given the discovery after that this concentration was likely at or slightly 
below the limit of detection for most of these drugs during the five quality control runs. 
However, the results from the 100 and 150 ng/mL quality control samples were on the 
whole, acceptable to be validated. Overall percent bias was acceptable for all drugs at 
these concentrations, with the exception of naloxone at 150 ng/mL.  
Between run precision results were also acceptable at the 100 and 150 ng/mL 
concentrations, with the exception of dihydrocodeine at 100 ng/mL, 6-MAM at 150 
ng/mL, and naloxone at both. The higher variety generally seen in the naloxone results 
could be in part because naloxone is the only drug in the method without its own specific 
designated internal standard, and the fentanyl deuterated internal standard was used 
instead.  
Within run precision was acceptable at the 5 ng/mL concentration across the board 
for fentanyl, and EDDP had acceptable precision in 4 of the 5 runs, but overall results 
varied far too much for most all the other drugs in the method. At 100 ng/mL however, 
within run precision was on the whole between the +/- 25% parameters, with the 
exception of dihydrocodeine, naloxone, and norfentanyl in two runs each, and in one run 
each for both oxymorphone and morphine. The run where morphine had unacceptable 
%CV was the same in which the r^2 was low. Finally, at 150 ng/mL, within run precision 
was acceptable for all compounds except for one run for buprenorphine, two runs for 
naloxone, and the same run -  run 2 - for morphine.  
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Overall, the trend is that as the concentrations got higher, the results became more 
reliably quantifiable. Once again, for these results too, it would be worth rerunning on a 
recalibrated mass spectrometer, or adjusting the calibrator points used to construct the 
calibration curves. Another factor to consider of course is user error, such as in pipetting, 
given that preparations for these samples involved large dilutions and small volumes, 
making very precise mixing and pipetting of samples imperative to limiting variation.  
For instance, using the error estimations provided in Eppendorf Research Plus 
Operating Manual36, the final volume of a 5 ng/mL sample after pipetting all of the 
necessary dilutions (after making the stock solution, serial dilutions of two 1:10 and one 
1:20 were performed) can fluctuate as much as approximately +/- 7.3%. This would mean 
that the final volume of the 500 uL sample could be as low as 463.5 uL, or as high as 
536.5 uL. This could affect the final concentration of the target metabolite, causing it to 
fall anywhere between approximately 4.66 ng/mL and 5.4 ng/mL. While these 
concentrations are within the target of +/- 25% accuracy, the potential error is still far 
more pronounced than for the 150 ng/mL samples, where less dilutions were necessary, 
and the same calculations estimate a final volume fluctuation to be +/- 4%, or a final 
concentration to be anywhere between 144.3 ng/mL and 156 ng/mL. These calculations 
help further demonstrate another reason why the lowest concentration pool may have 
been more susceptible to such wide variability. One way to combat this could be to use 
an automated pipetting robot in the future.  
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Interference & Carryover 
Overall, the average signal for the compounds at 5 and 15 ng/mL was significantly 
higher than the signals generated from the ten blank lots of urine for most all of the 
compounds. One notable exception is heroin, as six of the ten blank lots gave higher 
signals than the 15 ng/mL samples. There was also one lot of urine, lot #4, which gave a 
higher signal than the 15 ng/mL of morphine as well. These issues could potentially be 
addressed by adjusting the method, and choosing different Q3 fragments for these 
compounds that may not have such high levels of interference.  
In terms of common analyte interferences, two compounds seemed particularly 
susceptible to potential interference from the mixes of drugs analyzed. All three mixes 
produced signals for heroin higher than the average 15 ng/mL concentration signal, once 
again indicating that detection of heroin may benefit from the choice of a different 
product ion fragment less prone to interference. In addition, mix 3 yielded a signal higher 
than the average 15 ng/mL signal for norfentanyl, indicating that there could be some 
situations when abusing a drug from mix 3 in combination with norfentanyl could lead to 
an artificially high norfentanyl signal. Which drug exactly will require further 
experiments running an analysis of each individually. 
Finally, it does not seem that the metabolite diluent itself, or the deuterated internal 
standards, cause any significant signal interference. Additionally, the lack of signal in the 
double blank, which was run after the highest calibrator, indicates that there is also no 





The results here show that a panel of fourteen opioids can reliably be detected and 
distinguished using this ZipChip CE-MS/MS method, and can be quantified with 
reasonable bias and precision at the medium and high concentration quality control 
samples, 100 and 150 ng/mL. On the whole, the method provides a quick, accurate and 
efficient method for detecting and quantifying opioids. However, some compounds 
showed lower limits of detection than others, and depending on the intended application 
and the sensitivity required, at this stage in development, some laboratories may choose 
to employ this method as a more specific, informative screening technique than typical 
immunoassays. With some tweaking to the method and some further experiments, 
sensitivity can also likely be improved in order to reliably quantify even lower 
concentrations than the limits of detection calculated here, and become an even more 
efficient tool to help replace longer, more time-consuming LC-MS/MS methods for 
confirmatory testing and quantification of analytes. 
 Further Directions & Future Experiments  
In the future, the method could benefit from some fine tuning, and perhaps 
experimenting with the use of different product ions for compound identification could 
allow for higher sensitivity. Additionally, rerunning the samples and calibration curves 
on a recalibrated mass spectrometer could certainly be beneficial, as overall signals were 
not as high when the five calibration curves and quality control samples were run as they 
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were during the original test run a month earlier. This can help to elucidate the actual 
limit of quantitation, either by adjusting the range of the calibration curve, or rerunning it 
under more ideal conditions which hopefully yield higher levels of sensitivity. It is also 
worth noting that throughout this study, work was done to help improve the connection 
between the ZipChip unit and the inlet source on the SCIEX mass spectrometer, as the 
ZipChip was relatively recently adapted to fit this model. Future studies will likely 
benefit from an even better connection and consistent inlet source than was available at 
the time of these runs. 
 Furthermore, the experiments run here as a proof of concept were performed in 
metabolite diluent only, and in the future, experiments done by spiking the drugs into 
various biological matrices, such as urine and blood, should be performed. This will 
hopefully help to demonstrate one of the key benefits of electrophoresis – sample 
preparation can be limited to simple “dilute and shoot”, rather than more extensive 
extraction methods. More analytes and metabolites from other classes of drugs can also 
be added to the method, with the end goal of a comprehensive panel which can quickly 
and easily identify and quantify an extensive number of compounds of interest that may 
be forensically relevant.  
Finally, while the assessments here were done using a HS (high sensitivity) ZipChip, 
an HR (high resolution) ZipChip could also be tested, which has a longer capillary, and 
could possibly help to resolve and separate out a panel of drugs of interest with close 
retention times even further. Additionally, experimenting with the composition of the 
BGE is another way in which the method could be further optimized, and compounds of 
	
45 
interest separated out even further for clearer identification. The method can also be 
adapted and validated using other brands and models of mass spectrometers as well, 
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